Farydak (panobinostat) / Secura Bio  >>  Phase 2
Welcome,         Profile    Billing    Logout  

92 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Farydak (panobinostat) / Secura Bio
NCT00449761 / 2006-002011-27: Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase

Terminated
2
27
Europe, US
LBH589, Panobinostat
Novartis Pharmaceuticals
Leukemia, Myeloid, Chronic
01/08
08/08
NCT00451035: Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic Phase

Terminated
2
29
Europe
LBH589, Panobinostat
Novartis Pharmaceuticals
Chronic Myeloid Leukemia in Chronic Phase
04/08
09/08
NCT00445068 / 2006-004087-31: Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma

Terminated
2
38
Europe, US
LBH589, Panobinostat
Novartis Pharmaceuticals
Multiple Myeloma
05/08
12/09
NCT00699296: Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma

Terminated
2
4
Japan
Panobinostat (LBH589), LBH589
Novartis Pharmaceuticals
Cutaneous T-Cell Lymphoma, Leukemia-Lymphoma, Adult T-Cell
12/08
 
NCT00848523: Study of LBH589 (Panobinostat) to Treat Malignant Brain Tumors

Terminated
2
6
US
Panobinostat, LBH589
Neurological Surgery, P.C.
Recurrent Malignant Gliomas
04/09
04/09
NCT01222936 / 2007-007139-26: LBH Phase II in Small Cell Lung Cancer (SCLC)

Completed
2
21
Europe
LBH581, Panobinostat
Southern Europe New Drug Organization, Novartis Pharmaceuticals
Small Cell Lung Carcinoma
06/09
08/10
NCT00490776: Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)

Terminated
2
9
US
Panobinostat, LBH589
Novartis Pharmaceuticals
Cutaneous T-Cell Lymphoma
09/09
09/09
NCT00550277: LBH589 Treatment for Refractory Clear Cell Renal Carcinoma

Completed
2
20
US
LBH589, Panobinostat
SCRI Development Innovations, LLC, Novartis
Renal Cell Carcinoma
03/10
06/10
NCT00777335 / 2008-003175-45: Study of Panobinostat Monotherapy in Women With v-ERB-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) Positive Locally Recurrent or Metastatic Breast Cancer

Terminated
2
4
US
Panobinostat - LBH589
Translational Research in Oncology
Breast Cancer
03/10
03/10
NCT00723203: Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Terminated
2
16
US
panobinostat, gene expression analysis, reverse transcriptase-polymerase chain reaction, laboratory biomarker analysis
City of Hope Medical Center, National Cancer Institute (NCI)
Leukemia
09/10
09/10
2010-018699-26: Study with panobinostat maintenance therapy following stem cell transplantation in patients with high risk Myelodysplastic Syndrome or Acute Myeloic Leukemia

Ongoing
2
62
Europe
Panobinostat, LBH 589, Capsule, hard
Goethe Universität Frankfurt, Novartis Pharma GmbH
MDS and AML in patients with high risk features after hemapoietic stem cell transplantation with reduced conditioning, Myelodyspastic Syndrome and Acute Myeloblastic Leukemia in patients with high risk features after stem cell transplantation with reduced conditioning, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT00667862: Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer

Completed
2
35
US
Panobinostat, LBH589
Novartis Pharmaceuticals
Prostate Cancer
11/10
11/10
NCT01056601: Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy

Terminated
2
7
US
Bortezomib, Velcade, Panobinostat, LBH589
Masonic Cancer Center, University of Minnesota, Novartis Pharmaceuticals, Millennium Pharmaceuticals, Inc.
Pancreatic Cancer
02/11
02/11
NCT00594230: LBH589 in Refractory Myelodysplastic Syndromes (MDS)

Terminated
2
26
US
Panobinostat, LBH589
SCRI Development Innovations, LLC, Novartis Pharmaceuticals
Myelodysplastic Syndromes (MDS)
03/11
03/11
NCT01090973: Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)

Terminated
2
1
US
LBH589, panobinostat, HDAC Inhibitor
H. Lee Moffitt Cancer Center and Research Institute, Novartis Pharmaceuticals
Non-Hodgkin's Lymphoma
03/11
03/11
CLBH589C, NCT01115036: A Panobinostat Presurgery

Withdrawn
2
0
US
panobinostat, LBH589
Duke University, Novartis
Recurrent Glioblastoma
04/11
04/12
NCT00931762: A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis

Terminated
2
35
US
Panobinostat, LBH589, H-DAC Inhibitor
Novartis Pharmaceuticals
Primary Myelofibrosis, Post-Polycythemia Vera, Post-Essential Thrombocytopenia
08/11
08/11
NCT00936611: LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia

Completed
2
39
US
LBH589, panobinostat
Dana-Farber Cancer Institute, Brigham and Women's Hospital, Novartis
Waldenstrom's Macroglobulinemia
09/11
11/12
NCT00690677: Phase II Trial of LBH589 in Refractory Colorectal Cancer

Checkmark In pts with refractory mCRC
Aug 2014 - Aug 2014: In pts with refractory mCRC
Completed
2
29
US
LBH589
Swedish Medical Center, Novartis
Colorectal Cancer
12/11
12/11
ESTIM-LBH, NCT01136499 / 2009-011280-37: Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure

Completed
2
53
Europe
LBH589 (Panobinostat®), panobinostat
Centre Leon Berard
Soft Tissue Sarcoma
01/12
01/13
NCT00880269 / 2008-002983-32: Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)

Completed
2
59
US, Europe, RoW
Panobinostat/LBH589
Novartis Pharmaceuticals
Refractory Leukemia, Acute Myelogenous Leukemia
02/12
02/12
GEPARD, NCT01034657 / 2009-010403-84: LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS)

Terminated
2
34
Europe
LBH589, Panobinostat, Epoetin Alfa, ESA, HEXAL®
Novartis Pharmaceuticals
Myelodysplastic Syndrome (MDS)
08/12
08/12
NCT01528501 / 2008-002721-37: Histone Deacetylases - Gastric Cancer (HDAC-GaCa-2008)

Terminated
2
28
Europe
Panobinostat (LBH589)
Technische Universität München, Novartis
Metastatic Gastric Cancer
02/13
 
NCT01028313: A Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease

Withdrawn
2
0
US
LBH589, Panobinostat, Methylprednisolone, Medrol, Depo-Medrol
SCRI Development Innovations, LLC, Novartis
Chronic Graft-Versus-Host Disease
 
 
NCT00425555 / 2006-000880-27: Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma

Completed
2
139
Europe, Canada, US, RoW
Panobinostat, LBH589
Novartis Pharmaceuticals
Cutaneous T-Cell Lymphoma
06/13
06/13
NCT00939159: Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Terminated
2
17
US
LBH589
M.D. Anderson Cancer Center, Novartis Pharmaceuticals
Myelodysplastic Syndrome
06/13
06/13
NCT01013597: Trial of LBH589 in Metastatic Thyroid Cancer

Completed
2
13
US
LBH589, panobinostat
University of Wisconsin, Madison, Novartis Pharmaceuticals
Thyroid Carcinoma
08/13
02/16
NCT01282476: Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma

Terminated
2
18
US
Panobinostat with Rituximab, LBH589, LBH-569, Rituxan
Massachusetts General Hospital, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center
Diffuse Large B Cell Lymphoma
08/13
08/14
NCT00742027 / 2008-003016-35: Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma

Completed
2
129
Europe, US, RoW
Panobinostat, LBH589, LBH
Novartis Pharmaceuticals
Classical Hodgkin's Lymphoma
08/13
08/13
NCT00901147: Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma

Checkmark peripheral T-cell lymphoma
Dec 2015 - Dec 2015: peripheral T-cell lymphoma
Completed
2
25
RoW
panobinostat and bortezomib, LBH589B, Velcade
Singapore General Hospital
Peripheral T-cell Lymphoma (Not Otherwise Specified), Angioimmunoblastic T-cell Lymphoma, Extranodal NK/T-cell Lymphoma Nasal Type, Enteropathy- Type T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative), Relapsed ALCL (ALK-1 Positive) Post Autologous Transplant
01/14
01/14
NCT01523834 / 2011-000175-13: Oral Panobinostat Adult Patients DLBCL Relapsed/Refractory Stem Cell Transfusion (ASCT) or Not Eligible for ASCT

Completed
2
35
Europe
Panobinostat, LBH589
Fondazione Italiana Linfomi ONLUS
Diffuse Large B-cell Lymphoma
01/14
04/17
MACS1271, NCT01083602: Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma

Checkmark P2 data - (MM)
Nov 2013 - Nov 2013: P2 data - (MM)
Checkmark P3 data EHA 2012
May 2012 - May 2012: P3 data EHA 2012
Checkmark P2 data-ASCO
More
Completed
2
55
US
panobinostat, LBH589, PAN, bortezomib, BTZ, dexamethasone, DEX
Novartis Pharmaceuticals
Relapsed and Bortezomib Refractory Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse
02/14
02/14
NCT01658241: Panobinostat Biological Correlates Study

Completed
2
30
RoW
panobinostat, LBH589
Peter MacCallum Cancer Centre, Australia
Nodal Lymphoma, Lymphoma With Cutaneous Involvement, Lymphoma in Leukemic Phase, Marrow Involvement With Lymphoma, Multiple Myeloma
03/15
03/15
NCT00777049 / 2008-003176-21: Study of Panobinostat Monotherapy in Women With HER2-negative Locally Recurrent or Metastatic Breast Cancer

Completed
2
54
US
Panobinostat, LBH589
Translational Research in Oncology
Breast Cancer
04/15
04/15
NCT00985946: Study of Panobinostat in Patients With Neuroendocrine Tumors

Terminated
2
15
US
panobinostat (LBH589)
University of Wisconsin, Madison, Novartis Pharmaceuticals
Neuroendocrine Tumors
04/15
04/15
NCT00978432: Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Terminated
2
50
US
RAD001, Everolimus, LBH589, panobinostat, Doublet (RAD001 and LBH589)
Anne Beaven, MD, Novartis
Diffuse Large B-cell Lymphoma
04/15
03/16
2006-000881-35: A phase II, multicentre study of oral LBH589 in patients with chronic phase chronic myeloid leukemia with resistant disease following treatment with at least two BCR-ABL tyrosine kinase inhibitors

 
2
10
Europe
LBH589B, LBH589B,
Novartis Pharma Services AG, NOVARTIS FARMA
Adult Patients with chronic phase Ph+ CML whose disease is resistance following treatment with at least two BCR-ABL tyrosine kinase inhibitors (i.e., imatinib, nilotinib, or dasatinib).
 
07/08
2007-007939-29: A PHASE II,MULTI-CENTER, OPEN LABEL STUDY OF ORAL LBH589 PLUS MELPHALAN, PREDNISONE AND THALIDOMIDE (LB-MPT)IN ADVANCED, REFRACTORY MULTIPLE MYELOMA PATIENTS.

Ongoing
2
42
Europe
Thalidomide, Thalidomide
FONDAZIONE NEOPLASIE SANGUE ONLUS
Patients with refractory or advanced Multiple Myeloma.
 
 
2011-005847-29: An Open Label Phase II Study on the Use of Panobinostat in Combination with Bortezomib and Dexamethasone as Induction in Multiple Myeloma Patients Candidate to High-Dose Therapy Studio di fase II sull’uso di panobinostat associato a bortezomib e desametasone come terapia di induzione in pazienti con mieloma multiplo candidati ad una terapia ad alte dosi

 
2
65
Europe
Panobinostat, LBH589, VELCADE*INIET 1FL 3,5MG 1MG/ML, VELCADE*INIET 1FL 3,5MG 1MG/ML
OSPEDALE POLICLINICO S. MATTEO, Novartis Farma Spa
Multiple Myeloma patients candidate to high-dose therapy Mieloma multiplo in pazienti candati ad una terapia ad alte dosi
 
 
ACTRN12613000219785: Panobinostat maintenance in patients with multiple myeloma that have achieved less than complete remission following autologous stem cell transplantation.

Completed
2
25
 
The Alfred Hospital, THe Alfred Hospital
Multiple myeloma less than complete remission following Autologous Stem Cell Transplant
 
 
NCT01238692: A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)

Completed
2
42
Canada
LBH589, Panabinostat, Rituximab, MabThera IV
Sarit Assouline, Quebec Clinical Research Organization in Cancer, Novartis, Hoffmann-La Roche
Diffuse Large B Cell Lymphoma
01/16
12/16
NCT01261247: Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Completed
2
41
US
panobinostat, Faridak, HDAC inhibitor LBH589, histone deacetylase inhibitor LBH589, LBH589, laboratory biomarker analysis, western blotting, Blotting, Western, Western Blot, DNA analysis, flow cytometry, pharmacological study, pharmacological studies, immunohistochemistry staining method, immunohistochemistry
Mayo Clinic, National Cancer Institute (NCI)
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Peripheral T-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
05/16
12/19
NCT01460940: A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Completed
2
24
US
panobinostat, HDAC inhibitor, LBH589, hydroxamic acid, lenalidomide, CC-5013, Revlimid
Ohio State University Comprehensive Cancer Center, Celgene, Novartis
Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma
11/16
11/16
NCT01651039: Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM)

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Completed
2
32
US
Panobinostat, LBH589, Lenalidomide, Revlimid, Dexamethasone
Ajai Chari, Novartis Pharmaceuticals
Multiple Myeloma
12/16
12/16
PANORAMA4, NCT02720510: A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)

Terminated
2
6
US
Revlimid, lenalidomide, Velcade, bortezomib, dexamethasone, Decadron, Farydak, panobinostat, LBH589
Novartis Pharmaceuticals
Multiple Myeloma
05/17
05/17
NCT02290431: Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma

Completed
2
31
Japan
LBH589 (panobinostat), bortezomib, dexamethasone
Novartis Pharmaceuticals
Relapse/Refractory Multiple Myeloma
12/17
12/18
NCT02518750: Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma

Terminated
2
3
US
Dexamethasone, Decadron®, Panobinostat, LBH589, Liposomal vincristine, Vincristine sulfate liposome injection, VSLI, Marqibo®, Mitoxantrone, Novantrone®, Peg-asparaginase, Peg-L-asparaginase, Pegaspargase, Oncaspar®, Bortezomib, Velcade, MLN341, LDP-341, Intrathecal Triples, ITMHA, Methotrexate/Hydrocortisone/Cytarabine, High-dose methotrexate, HDMTX, 6-Mercaptopurine, 6-MP, Purinethol®, High-dose cytarabine, Ara-C, Cytosar-U®, Nelarabine, Arranon®, Compound 506U78, Cyclophosphamide, Cytoxan®, Etoposide, VP-16, Vepesid®, Clofarabine, Clolar™, Clofarex
St. Jude Children's Research Hospital, Novartis Pharmaceuticals, Spectrum Pharmaceuticals, Inc
Acute Lymphoblastic Leukemia, Lymphoma, Non-Hodgkin's, Leukemia, T-Cell, Leukemia, B-Cell
03/18
03/18
NCT01802879 / 2012-005252-41: Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator

Completed
2
9
Europe, US, RoW
Panobinostat
Novartis Pharmaceuticals
Hematologic Neoplasms
11/18
11/18
NCT02588339: Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention

Completed
2
42
US
Panobinostat, PANO, Farydak, LBH-589, Sirolimus, SIR, Rapamune, Tacrolimus, TAC, Prograf
H. Lee Moffitt Cancer Center and Research Institute, Novartis
Graft Versus Host Disease, GVHD
12/18
07/21
PANORAMA_3, NCT02654990 / 2015-001564-19: Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma

Completed
2
249
Europe, Canada, US, RoW
panobinostat capsules, PAN, LBH589, bortezomib injection, BTZ, dexamethasone tablets, Dex
pharmaand GmbH, Novartis Pharma Services AG, Secura Bio, Inc.
Multiple Myeloma
10/19
08/22
NCT02722941: Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)

Completed
2
30
US
Panobinostat, LBH589
H. Lee Moffitt Cancer Center and Research Institute, Novartis Pharmaceuticals
Multiple Myeloma
06/20
01/21
2020-003395-41: Ex vivo drug sensitivity in metastatic colorectal cancer

Not yet recruiting
2
45
Europe
Alectinib, Crizotinib, Dasatinib, Everolimus, Gemcitabine, Idelalisib, Larotrectinib, Methotrexate, Palbociclib, Panobinostat, Pembrolizumab, Pertuzumab, Trastuzumab, Talazoparib, Venetoclax, Cetuximab, Encorafinib, Capsule, hard, Film-coated tablet, Tablet, Infusion, Injection, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Alecensa, Xalkori, Sprycel, Afinitor, Gemcitabine Accord, Zydelig, Vitrakvi, Methotrexat Accord, Ibrance, Farydak, Keytruda, Perjeta, Herceptin, Talzenna, Venclyxto, Erbitux, Braftovi
Oslo University Hospital, Oslo University Hospital
Metastatic Colorectal Cancer, Metastatic Colorectal Cancer, Diseases [C] - Cancer [C04]
 
 
PANORAMA-5, NCT02756663: Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

Withdrawn
2
0
US, Canada, Europe, RoW
panobinostat (capsules), PAN, LBH589, carfilzomib (infusion), CFZ, dexamethasone (tablets), Dex
Novartis Pharmaceuticals
Multiple Myeloma
02/21
02/21
NCT03256045: Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Terminated
2
9
US
Carfilzomib, Kyprolis, PR-171, Chemosensitivity Assay, Chemosensitivity Testing, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Laboratory Biomarker Analysis, Panobinostat, Faridak, Farydak, LBH589
University of Washington, National Cancer Institute (NCI), SecuraBio
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
02/21
02/21
NCT02961816: Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma

Withdrawn
2
0
NA
Palifermin, Kepivance, Panobinostat, LBH589B, Gemcitabine, Gemcitabine Hydrochloride, Gemzar, Busulfan, Busulfex, Myleran, Melphalan, Alkeran, Rituximab, Rituxan, Dexamethasone, Decadron, Caphosol, Glutamine, Enterex, Glutapak-10, NutreStore, Resource, GlutaSolve, Sympt-X G.I., Sympt-X, Oral Cryotherapy (ice chips), Pyridoxine, Stem Cell Infusion, Stem Cell Transplant, G-CSF, Filgrastim, Neupogen
M.D. Anderson Cancer Center
Lymphoma
06/21
06/21
NORTH, NCT04897880 / ACTRN12618000321246: A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT

Terminated
2
25
US, RoW
Panobinostat, Farydak®
Australian & New Zealand Children's Haematology/Oncology Group, National Health and Medical Research Council, Australia, Secura Bio, Inc.
Rhabdoid Tumor, Atypical Teratoid/Rhabdoid Tumor, Malignant Rhabdoid Tumor, Recurrent Brain Tumor, Childhood
12/21
12/21
ACTRN12618000321246: A Phase II Study of Panobinostat in Paediatric, Adolescent and Young Adult Patients with Solid Tumours Including Osteosarcoma, Malignant Rhabdoid Tumour/Atypical Teratoid Rhabdoid Tumours and Neuroblastoma.

Active, not recruiting
2
60
 
Australian and New Zealand Children’s Haematology and Oncology Group (ANZCHOG), NHMRC
Osteosarcoma, Malignant Rhabdoid Tumour, Neuroblastoma, Atypical Teratoid/Rhabdoid Tumour (AT/RT)
 
 
2020-000382-16: Efficacy of daratumumab (Dara) retreatment of relapsed/ refractory multiple myeloma (RRMM) patients in combination with panobinostat, bortezomib-and dexamethasone Wirksamkeit einer wiederholten Daratumumab (Dara) Behandlung von Patienten mit rezidiviertem/refraktärem Multiplen Myelom (RRMM) in Kombination mit Panobinostat, Bortezomib und Dexamethason

Not yet recruiting
2
30
Europe
Darzalex, Farydak, Velcade, L01XC24, L01XX42, L01XX32, Concentrate for solution for injection, Capsule, hard, Powder for solution for injection, Daratumumab (DARZALEX® 1.800 mg Injektionslösung), Farydak (Panobinostat), Velcade (Bortezomib)
Medical Center - University of Freiburg, University of Freiburg, Faculty of Medicine, Janssen-Cilag GmbH
Relapsed and refractory multiple myeloma Rezidives und refraktäres Multiples Myelom, Relapsed and refractory multiple myeloma wiederkehrendes / therapieresistentes Multiples Myelom, Diseases [C] - Cancer [C04]
 
 
NCT02506959: Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

Completed
2
83
US
Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Autologous, Autologous Hematopoietic Cell Transplantation, Autologous Stem Cell Transplant, Autologous Stem Cell Transplantation, Stem Cell Transplantation, Autologous, Busulfan, 1, 4-Bis[methanesulfonoxy]butane, BUS, Bussulfam, Busulfanum, Busulfex, Busulphan, CB 2041, CB-2041, Glyzophrol, GT 41, GT-41, Joacamine, Methanesulfonic Acid Tetramethylene Ester, Methanesulfonic acid, tetramethylene ester, Mielucin, Misulban, Misulfan, Mitosan, Myeleukon, Myeloleukon, Myelosan, Mylecytan, Myleran, Sulfabutin, Tetramethylene Bis(methanesulfonate), Tetramethylene bis[methanesulfonate], WR-19508, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, FF 10832, FF-10832, FF10832, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Laboratory Biomarker Analysis, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Panobinostat, Faridak, LBH589, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood, Peripheral Blood Progenitor Cell Transplantation, PERIPHERAL BLOOD STEM CELL TRANSPLANT, Peripheral Stem Cell Support, Peripheral Stem Cell Transplant, Peripheral Stem Cell Transplantation, Pharmacological Study
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Plasma Cell Leukemia, Plasmacytoma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
06/24
06/24
NCT03632317: A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas

Withdrawn
2
0
US
Panobinostat, Everolimus
University of Michigan Rogel Cancer Center
Glioma, Diffuse Intrinsic Pontine Glioma
10/25
10/25
EVIDENT, NCT05725200: Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

Recruiting
2
40
Europe
Alectinib, Cetuximab, Crizotinib, Dasatinib, Everolimus, Encorafenib, Gemcitabine, Idelalisib, Larotrectinib, Methotrexate, Palbociclib, Panobinostat, Pembrolizumab, Petrozumab, Trastuzumab, Talazoparib, Venetoclax
Oslo University Hospital
Metastatic Colorectal Cancer
12/38
12/40
ACTRN12612000746831: A Phase I/II trial to determine the Safety, Toxicity and Efficacy of Iodine-131-Rituximab and the Histone Deacetylase Inhibitor Panobinostat in Relapsed and Refractory Indolent B-cell Lymphoma

Recruiting
1/2
30
 
Peter MacCallum Cancer Centre, Peter MacCallum Cancer Centre, Novartis Pharmaceuticals Australia Pty Limited
Relapsed and Refractory Indolent B-cell Lymphoma
 
 
ACTRN12612000779875: To explore the tolerance and activity of increasing doses of Panobinostat when given in combination with Bortezomib, Cyclophosphamide and Dexamethasone to patients with symptomatic Multiple Myeloma who have had no previous treatment.

Withdrawn
1/2
37
 
North Shore Haematology Clinical Trial Unit, Novartis Pharmaceuticals Australia Pty Limited
Multiple Myeloma (Treatment Naive)
 
 
NCT00621244 / 2005-003670-26: A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies

Completed
1/2
175
Europe, US, RoW
LBH589
Novartis Pharmaceuticals
Lymphoma, Leukemia, Multiple Myeloma
12/09
12/09
NCT00567879 / 2007-002449-19: A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab

Terminated
1/2
56
US, Canada, Europe
Panobinostat, Trastuzumab, Herceptin
Novartis Pharmaceuticals
Breast Cancer
05/11
05/11
ACTRN12610000924055: Panobinostat with 5-azacytidine in patients with untreated high risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukaemia (AML).

Completed
1/2
40
 
The Alfred Hospital, The Alfred Hospital
Previously untreated high risk Myelodysplastic syndrome (MDS), Previously untreated Acute Myeloid Leukaemia (AML)
 
 
NCT00743288: Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma

Checkmark P1/2 data ASCO
Jun 2012 - May 2012: P1/2 data ASCO
Completed
1/2
40
US
Melphalan, Phenylalanine mustard, Alkeran, Panobinostat, LBH589
Oncotherapeutics, Novartis
Multiple Myeloma
11/12
12/12
NCT00691938: LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)

Completed
1/2
52
US
LBH589, Panobinostat, Decitabine, Dacogen, 5-aza-2'-deoxycytidine
Washington University School of Medicine
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
07/13
08/14
NCT01105312: Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer

Completed
1/2
28
US
letrozole, panobinostat, RNA analysis, microarray analysis, reverse transcriptase-polymerase chain reaction, enzyme-linked immunosorbent assay, immunohistochemistry staining method, laboratory biomarker analysis
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Breast Cancer
08/13
09/13
NCT00859222: LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma

Completed
1/2
51
US
LBH589, panobinostat, Farydak, bevacizumab, Avastin
Patrick Y. Wen, MD, Brigham and Women's Hospital, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Northwestern University, University of Virginia, Genentech, Inc., Novartis
Malignant Glioma
09/13
12/15
CLEAR, NCT01680094 / 2012-000240-94: Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART

Completed
1/2
15
Europe
Panobinostat, LBH589
University of Aarhus, Massachusetts General Hospital, Monash University, University of Sydney, Novartis, Aarhus University Hospital
HIV Infection
09/13
01/14
NCT01194908: Re-expression of ER in Triple Negative Breast Cancers

Terminated
1/2
5
US
Decitabine, LBH589, Tamoxifen, LBH589, Decitabine, Dacogen, Novaldex
Emory University, Novartis, Eisai Inc.
Breast Cancer, Breast Tumors, Breast Neoplasms
01/14
01/14
NCT00967044: Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma

Checkmark panobinostat+everolimus in pts with relapsed/refractory lymphoma
Oct 2013 - Oct 2013: panobinostat+everolimus in pts with relapsed/refractory lymphoma
Completed
1/2
31
US
Panobinostat, LBH589, Everolimus, Afinitor, RAD001
M.D. Anderson Cancer Center, Novartis
Lymphoma
03/14
03/14
NCT00925132: Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat

Checkmark For the treatment of resistant metastatic melanoma
Jul 2014 - Jul 2014: For the treatment of resistant metastatic melanoma
Terminated
1/2
39
US
Temozolomide, Decitabine, Panobinostat, LBH589
University of Iowa, Holden Comprehensive Cancer Center, Novartis Pharmaceuticals
Metastatic Melanoma
11/14
12/16
NCT00878436: Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Completed
1/2
52
US
Panobinostat, LBH589, Bicalutamide, Casodex
NYU Langone Health, Novartis
Prostate Cancer, Prostatic Neoplasms
03/15
07/15
NCT01298934: LBH589 (Panobinostat) for the Treatment of Myelofibrosis

Unknown status
1/2
22
US
LBH589, Panobinostat
Ronald Hoffman, Novartis
Primary Myelofibrosis, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Post-Essential Thrombocythemia Related Myelofibrosis
07/15
07/15
MUKsix, NCT02145715 / 2012-000842-36: Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma

Unknown status
1/2
54
Europe
Velcade, Bortezomib, Thalidomide, Dexamethasone, Panobinostat
Prof Jamie Cavenagh, Myeloma UK, Novartis
Multiple Myeloma
07/15
01/16
NCT01582009: Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate

Terminated
1/2
26
US
panobinostat, Faridak, HDAC inhibitor LBH589, histone deacetylase inhibitor LBH589, LBH589, everolimus, 42-O-(2-hydroxy)ethyl rapamycin, Afinitor, RAD001, laboratory biomarker analysis, pharmacological study, pharmacological studies, liquid chromatography, LC, mass spectrometry, enzyme-linked immunosorbent assay, ELISA, immunohistochemistry staining method, immunohistochemistry
Roswell Park Cancer Institute, Novartis
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
10/15
12/15
NCT01111526: Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD)

Completed
1/2
22
US
Panobinostat (LBH589)
H. Lee Moffitt Cancer Center and Research Institute, Novartis
Graft-Versus-Host Disease
10/15
06/16
NCT00918333: Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma

Completed
1/2
124
US
panobinostat, Faridak, HDAC inhibitor LBH589, histone deacetylase inhibitor LBH589, LBH589, everolimus, 42-O-(2-hydroxy)ethyl rapamycin, Afinitor, RAD001, laboratory biomarker analysis, pharmacological study, pharmacological studies
Mayo Clinic, National Cancer Institute (NCI)
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Primary Central Nervous System Non-Hodgkin Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Splenic Marginal Zone Lymphoma, T-cell Adult Acute Lymphoblastic Leukemia, Waldenström Macroglobulinemia
12/15
07/19
2012-003344-74: A study to evaluate the efficacy and safety of combination chemotherapy of panobinostat and decitabine, given after donor stem cell transplantation in patients with (very) poor risk AML

Ongoing
1/2
70
Europe
panobinostat, Dacogen, Dacogen
HOVON Foundation, Dutch Cancer Society, Novartis, Janssen Cilag, HOVON Foundation
(very) poor risk AML or RAEB with IPSS ≥ 1.5
 
 
PANOBIDARA, NCT00840346: Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML)

Completed
1/2
46
Europe
panobinostat
PETHEMA Foundation
Acute Myeloblastic Leukaemia
05/16
12/18
NCT01169636: Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma

Completed
1/2
62
US
Panobinostat, LBH589B, Ifosfamide, Ifex, Mesna, Mesnex, Carboplatin, Paraplatin, Etoposide, VePesid, Pegfilgrastim, Neulasta, PEG-G-CSF
M.D. Anderson Cancer Center, Novartis
Hodgkin's Lymphoma
05/17
05/17
PANOBEST, NCT01451268: Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)

Unknown status
1/2
62
Europe
Panobinostat, LBH589
Johann Wolfgang Goethe University Hospital
Myelodysplastic Syndrome, Acute Myeloid Leukemia
04/18
04/18
2017-002335-42: A study about the treatment of patients with a specific type of AML with a combination of panobinostat and midostaurin during 1 year after allogeneic stem cell transplantation . Onderzoek naar de behandeling van patiënten met een specifiek type AML, met de middelen panobinstat en midostaurin gedurende 1 jaar na donor-stamceltransplantatie.

Ongoing
1/2
40
Europe
panobinostat, Midostaurin, Capsule, Farydak 20 mg, Rydapt
HOVON Foundation, Novartis
adverse risk AML or RAEB, 'High risk' acute myeloid leukemia of myedysplastic syndrome, Diseases [C] - Cancer [C04]
 
 
NCT02057640: MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma

Completed
1/2
16
US
Panobinostat, Dexamethasone, MLN9708, Ixazomib
Jason Valent
Multiple Myeloma, Kahler Disease, Plasma-Cell Myeloma, Myelomatosis
05/18
05/18
PRIME, NCT01693601: Panobinostat and Ruxolitinib In MyElofibrosis ( Trial)

Completed
1/2
15
US
Panobinostat, LBH589, Ruxolitinib, INCB424, Jakafi
John Mascarenhas
Myelofibrosis
05/18
05/18
NCT00946647 / 2009-010548-32: A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).

Completed
1/2
113
Europe, Canada, US, RoW
Panobinostat (LBH589), 5-Azacytidine
Novartis Pharmaceuticals
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
04/19
04/19
NCT02802163: Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat

Withdrawn
1/2
0
NA
Panobinostat, LBH589, deacetylase inhibitor (DACi), Carfilzomib, Kyprolis, Lenalidomide, Revlimid, Dexamethasone, Decadron, corticosteroid
H. Lee Moffitt Cancer Center and Research Institute, Novartis, Amgen
Multiple Myeloma
09/20
12/20
NCT01496118: Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark relapsed/refractory multiple myeloma
Feb 2015 - Feb 2015: relapsed/refractory multiple myeloma
Completed
1/2
80
US
panobinostat, LBH589 (Panobinostat), carfilzomib, PX-171-007
SCRI Development Innovations, LLC, Onyx Therapeutics, Inc., Novartis
Multiple Myeloma
12/20
12/20
ACTIVATE, NCT02471430: Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy

Completed
1/2
17
US
Panobinostat, Farydak, LBH589, Pegylated Interferon-alpha2a, Pegasys
Massachusetts General Hospital, Novartis, Genentech, Inc.
HIV Infection
08/22
12/23
ORBIT, NCT06240520: Optimizing Reversal of HIV Latency With Combination Therapy

Not yet recruiting
1/2
49
Europe
Panobinostat 20 MG Oral Capsule, Pyrimethamine 200mg Oral Tablet, Lenalidomide 25 MG Oral Capsule
Erasmus Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development, AIDSfonds
Hiv
05/25
10/25

Download Options